Role of DRD2 and ALDH2 genes in bipolar II disorder with and without comorbid anxiety disorder

European Psychiatry

Volumn 29, Issue 3, 2014, Pages 142-148

  Wang, Y S ^a   Lee, S Y ^b   Chen, S L ^b   Chang, Y H ^c   Wang, T Y ^b,d   Lin, S H ^b   Wang, C L ^b   Huang, S Y ^e   Lee, I H ^b   Chen, P S ^b   Yang, Y K ^a,b   Lu, R B ^a,b,c  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d Tainan Hospital   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

ALDH2; Anxiety disorders; Bipolar II disorder; DRD2

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2; DOPAMINE 2 RECEPTOR; ALDEHYDE DEHYDROGENASE; ALDH2 PROTEIN, HUMAN; DRD2 PROTEIN, HUMAN;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR II DISORDER; COMORBIDITY; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ANXIETY DISORDERS; BIPOLAR DISORDER; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PHYSIOLOGY;

ADULT; ALDEHYDE DEHYDROGENASE; ANXIETY DISORDERS; BIPOLAR DISORDER; COMORBIDITY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2;

EID: 84896727039     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2013.05.001     Document Type: Article

References (58)

1. Agarwal D.P., Goedde H.W. Pharmacogenetics of alcohol metabolism and alcoholism. Pharmacogenetics 1992, 2:48-62.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorder-TR 2000, American Psychiatric Association, Washington. 5th ed.
3. Angst J. Panic disorder: history and epidemiology. Eur Psychiatry 1998, 13(Suppl.2):51s-55s.
4. Angst J. The bipolar spectrum. Br J Psychiatry 2007, 190:189-191.
5. Boylan K.R., Bieling P.J., Marriott M., Begin H., Young L.T., MacQueen G.M. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 2004, 65:1106-1113.
6. Carlson C.S., Eberle M.A., Kruglyak L., Nickerson D.A. Mapping complex disease loci in whole-genome association studies. Nature 2004, 429:446-452.
7. Chang Y.H., Chen S.L., Chen S.H., et al. Low anxiety disorder comorbidity rate in bipolar disorders in Han Chinese in Taiwan. Progr Neuropsychopharmacol Biol Psychiatry 2012, 36:194-197.
8. Chen C.C., Lu R.B., Chen Y.C., et al. Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am J Hum Genet 1999, 65:795-807.
9. Comings D.E. Molecular heterosis as the explanation for the controversy about the effect of the DRD2 gene on dopamine D2 receptor density. Mol Psychiatry 1999, 4:213-215.
10. Coryell W., Endicott J., Maser J.D., Keller M.B., Leon A.C., Akiskal H.S. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995, 152:385-390.
11. Crabb D.W., Edenberg H.J., Bosron W.F., Li T.K. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. J Clin Invest 1989, 83:314-316.
12. Craddock N., Sklar P. Genetics of bipolar disorder: successful start to a long journey. Trends Genet 2009, 25:99-105.
13. Dandre F., Cassaigne A., Iron A. The frequency of the mitochondrial aldehyde dehydrogenase I2 (atypical) allele in Caucasian, Oriental and African black populations determined by the restriction profile of PCR-amplified DNA. Mol Cell Probes 1995, 9:189-193.
14. Doughty C.J., Wells J.E., Joyce P.R., Olds R.J., Walsh A.E. Bipolar-panic disorder comorbidity within bipolar disorder families: a study of siblings. Bipolar Disord 2004, 6:245-252.
15. Endicott J., Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978, 35:837-844.
16. Freeman M.P., Freeman S.A., McElroy S.L. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 2002, 68:1-23.
17. Gerner R.H., Post R.M., Bunney W.E. A dopaminergic mechanism in mania. Am J Psychiatry 1976, 133:1177-1180.
18. Grandy D.K., Zhang Y., Civelli O. Pcr detection of the Taqa Rflp at the Drd2 locus. Hum Mol Genet 1993, 2:2197.
19. Hayden E.P., Klein D.N., Dougherty L.R., et al. The dopamine D2 receptor gene and depressive and anxious symptoms in childhood: associations and evidence for gene-environment correlation and gene-environment interaction. Psychiatr Genet 2010, 20:304-310.
20. Huang S.Y., Lin W.W., Ko H.C., et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004, 28:374-384.
21. Jonsson E.G., Nothen M.M., Grunhage F., et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999, 4:290-296.
22. Joshi G., Wilens T. Comorbidity in pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am 2009, 18:291-319.
23. Judd L.L., Akiskal H.S., Schettler P.J., et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders. J Affect Disord 2003, 73:19-32.
24. Keck P.E., McElroy S.L., Arnold L.M. Bipolar disorder. Med Clin North Am 2001, 85:645-661.
25. Kelsoe J.R. Arguments for the genetic basis of the bipolar spectrum. J Affect Disord 2003, 73:183-197.
26. Keung W.M., Vallee B.L. Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase. Proc Natl Acad Sci U S A 1993, 90:1247-1251.
27. Keung W.M., Vallee B.L. Daidzin and its antidipsotropic analogs inhibit serotonin and dopamine metabolism in isolated mitochondria. Proc Natl Acad Sci U S A 1998, 95:2198-2203.
28. Kirov G., Jones I., McCandless F., Craddock N., Owen M.J. Family-based association studies of bipolar disorder with candidate genes involved in dopamine neurotransmission: DBH, DAT1, COMT, DRD2, DRD3 and DRD5. Mol Psychiatry 1999, 4:558-565.
29. Klein D.N., Riso L.P. Psychiatric disorders problems of boundaries and comorbidity. Basic issues in psychopathology 1993, 19-66. Guilford Press, New York. C.G. Costello (Ed.).
30. Lamensdorf I., Eisenhofer G., Harvey-White J., Nechustan A., Kirk K., Kopin I.J. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 2000, 868:191-201.
31. Lee H.C., Lee H.S., Jung S.H., et al. Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. J Korean Med Sci 2001, 16:745-750.
32. Lee S.Y., Chen S.L., Chang Y.H., et al. The ALDH2 and DRD2/ANKK1 genes interacted in bipolar II but not bipolar I disorder. Pharmacogenet Genomics 2010, 20:500-506.
33. Leszczynska-Rodziewicz A., Hauser J., Dmitrzak-Weglarz M., et al. Lack of association between polymorphisms of dopamine receptors, type D2, and bipolar affective illness in a Polish population. Med Sci Monit 2005, 11:289-295.
34. Li T., Liu X.H., Sham P.C., et al. Association analysis between dopamine receptor genes and bipolar affective disorder. Psychiatry Res 1999, 86:193-201.
35. Mann J.J., Kapur S. A dopaminergic hypothesis of major depression. Clin Neuropharmacol 1995, 18:S57-S65.
36. McGuffin P., Rijsdijk F., Andrew M., Sham P., Katz R., Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003, 60:497-502.
37. McIntyre R.S., Soczynska J.K., Bottas A., Bordbar K., Konarski J.Z., Kennedy S.H. Anxiety disorders and bipolar disorder: a review. Bipolar Disord 2006, 8:665-676.
38. Nakamura K., Iwahashi K., Matsuo Y., Miyatake R., Ichikawa Y., Suwaki H. Characteristics of Japanese alcoholics with the atypical aldehyde dehydrogenase 2*2. I. A comparison of the genotypes of ALDH2, ADH2, ADH3, and cytochrome P-4502E1 between alcoholics and nonalcoholics. Alcohol Clin Exp Res 1996, 20:52-55.
39. Nierenberg A.A., Dougherty D., Rosenbaum J.F. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry 1998, 59(Suppl.5):60-63.
40. Noble E.P., Gottschalk L.A., Fallon J.H., Ritchie T.L., Wu J.C. D2 dopamine receptor polymorphism and brain regional glucose metabolism. Am J Med Genet 1997, 74:162-166.
41. Nothen M.M., Erdmann J., Korner J., et al. Lack of association between dopamine D1 and D2 receptor genes and bipolar affective disorder. Am J Psychiatry 1992, 149:199-201.
42. Pallanti S., Quercioli L., Pazzagli A., et al. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. Am J Psychiatry 1999, 156:1094-1096.
43. Pearlson G.D., Wong D.F., Tune L.E., et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995, 52:471-477.
44. Rakofsky J.J., Ressler K.J., Dunlop B.W. BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. Mol Psychiatry 2012, 17:22-35.
45. Rooke N., Li D.J., Li J., Keung W.M. The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin. J Med Chem 2000, 43:4169-4179.
46. Rotondo A., Mazzanti C., Dell'Osso L., et al. Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 2002, 159:23-29.
47. Simon N.M., Otto M.W., Wisniewski S.R., et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004, 161:2222-2229.
48. Sipila T., Kananen L., Greco D., et al. An association analysis of circadian genes in anxiety disorders. Biol Psychiatry 2010, 67:1163-1170.
49. Smith E.N., Bloss C.S., Badner J.A., et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry 2009, 14:755-763.
50. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
51. Souery D., Lipp O., Mahieu B., et al. Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes. Am J Med Genet 1996, 67:551-555.
52. Spitzer R.L., Endicott J., Williams J.B. Research diagnostic criteria. Arch Gen Psychiatry 1979, 36:1381-1383.
53. Tamam L. [Comorbid anxiety disorders in bipolar disorder patients: a review]. Turk Psikiyatri Derg 2007, 18:59-71.
54. Taylor A.E., Saint-Cyr J.A. Depression in Parkinson's disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci 1990, 2:92-98.
55. Vieta E., Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord 2008, 10:163-178.
56. Vieta E., Gasto C., Otero A., Nieto E., Vallejo J. Differential features between bipolar I and bipolar II disorder. Compr Psychiatry 1997, 38:98-101.
57. Wozniak J., Biederman J., Monuteaux M., Richards J., Faraone S.V. Parsing the comorbidity between bipolar disorder and anxiety disorders: a familial risk analysis. J Child Adolesc Psychopharmacol 2002, 12:101-111.
58. Zutshi A., Reddy Y.C., Thennarasu K., Chandrashekhar C.R. Comorbidity of anxiety disorders in patients with remitted bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2006, 256:428-436.